Camurus AB (publ)
Camurus AB (publ), a pharmaceutical company, develops and commercializes pharmaceuticals for serious and chronic conditions in Europe, Australia, the United States, Japan, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence; and episil oral liquid, a medical device for the treatment of inflammatory and painful conditions in the oral cavity. Its products pipeline also includes Brixadi for opioid dependence; CAM2038 that is in phase III clinical trials for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors; and CAM2043 that is in Phase II clinical trials for treatment of pulmonary arterial hypertension and Raynaud's phenomenon.
In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which has completed Phase I clinical trials for the treatment of Endocrine disorder; CAM4083 for treatment of myasthenia gravis and other serious tissue-based complement-mediated disorders; CAM2047 for the treatment of chemotherapy induced nausea and vomiting; and CAM2048 for postoperative pain.
Based on sector and market capitalization